Clinical Trials Logo

Bullous Keratopathy clinical trials

View clinical trials related to Bullous Keratopathy.

Filter by:

NCT ID: NCT05956535 Enrolling by invitation - Corneal Edema Clinical Trials

Air Optix® Night and Day® Aqua Therapeutic Wear

Start date: September 26, 2023
Phase:
Study type: Observational

The purpose of this study is to support the safety and performance assessment of Air Optix Night and Day Aqua (AONDA) soft contact lenses for therapeutic use in accordance with updated EU Medical Device Regulation (MDR) requirements.

NCT ID: NCT05891106 Completed - Corneal Ulcer Clinical Trials

AONDA Therapeutic Indication Study I

Start date: June 28, 2023
Phase:
Study type: Observational

This study will be used to support assessment of AIR OPTIX® NIGHT & DAY® AQUA (AONDA) Soft Contact Lenses' safety and performance in accordance with updated European Union Medical Device Regulation (EU MDR) requirements.

NCT ID: NCT05636579 Recruiting - Clinical trials for Endothelial Dysfunction

Study to Assess Safety and Tolerability of Multiple Doses of EO2002

Start date: December 1, 2022
Phase: Phase 1
Study type: Interventional

The goal of this clinical study is to assess the safety of multiple intracameral injections of EO2002 with and without topical Ripasudil.

NCT ID: NCT05436665 Recruiting - Clinical trials for Fuchs' Endothelial Dystrophy

The Belgian Endothelial Surgical Transplant of the Cornea

BESTCornea
Start date: August 10, 2022
Phase: N/A
Study type: Interventional

This study is designed as a randomised multicentric parallel group pragmatic trial of Descemet Stripping Automated Endothelial Keratoplasty (DSAEK) versus Descemet Membrane Endothelial Keratoplasty (DMEK) in corneal endothelial decompensation. the purpose is to compare the clinical and patient reported outcomes of both therapies across a broad range of indications.

NCT ID: NCT04894110 Active, not recruiting - Clinical trials for Endothelial Dysfunction

Study of Safety and Tolerability of EO2002 in the Treatment of Corneal Edema

Start date: June 22, 2021
Phase: Phase 1
Study type: Interventional

Corneal edema is the most common indication for corneal transplantation, accounting for approximately 70% of penetrating keratoplasty (PK), and 100% of endothelial keratoplasty (EK) procedures annually. There is currently no disease-modifying treatment for corneal edema. Topical treatments like hypertonic saline are not effective on a long-term basis. For those with advanced disease, where edema and vision loss are not controlled by topical treatment, the only option is a corneal transplant. A potential approach to avoidance of the risks of corneal transplantation is to inject cultured human corneal endothelial cells (HCECs) into the anterior chamber of the eye. This approach may avoid surgery by re-populating the inner most aspect of the cornea with functioning endothelial cells. Emmecell has developed a treatment based on technology integrating biocompatible magnetic nanoparticles with cultured HCECs to treat corneal edema in a minimally invasive way. The primary objective of this phase 1, prospective, multi-center, open-label, dose-escalation study is to evaluate the safety and tolerability of 3 doses of EO2002 with and without endothelial brushing (EB) or Descemet Stripping (DS) in eyes with corneal edema secondary to corneal endothelial dysfunction that qualify for surgery involving full-thickness corneal transplantation or EK.

NCT ID: NCT04319848 Recruiting - Clinical trials for Fuchs' Endothelial Dystrophy

Safety and Efficacy of Tissue Engineered Endothelial Keratoplasty

TE-EK
Start date: December 1, 2017
Phase: Phase 1
Study type: Interventional

Assessment of safety and efficacy of tissue-engineered corneal endothelial graft material generated using cultured human corneal endothelial cells for tissue-engineered endothelial keratoplasty (TE-EK).

NCT ID: NCT03763721 Completed - Vision Disorders Clinical Trials

The ADVISE Study: Advanced Visualization In Corneal Surgery Evaluation

ADVISE
Start date: November 13, 2018
Phase: N/A
Study type: Interventional

Rationale: Intra-operative optical coherence tomography (iOCT) is a new technology that incorporates advanced imaging techniques in the ophthalmic operating theatre. This allows surgeons to visualize tissues in a way previously impossible We conceptualized an iOCT-guided surgical protocol for the treatment of endothelial cell dysfunction, that refrains from the current practice of over-pressurizing the eye at the end of surgery. Objective: The aim of this study is to assess the clinical value of intraoperative OCT (iOCT) for Descemet Membrane Endothelial Keratoplasty (DMEK) by comparing an iOCT-optimized surgical protocol with current practice, where the eye is over-pressurized for a set period of time, in terms of surgical efficiency, clinical outcomes, and adverse events. Study design: International multicentre non-inferiority randomized clinical trial Study population: Patients scheduled for posterior lamellar corneal surgery for endothelial cell dysfunction above the age of 18 years. Intervention: Both groups will undergo Descemet Membrane Endothelial Keratoplasty. Patients will be randomized for either the iOCT optimized surgical protocol or current standard surgical protocol using 8 minutes of overpressure to facilitate graft adherence. Both groups will be evaluated with iOCT at the end of surgery. Main study parameters/endpoints: The main study parameter is the rate of adverse events (particularly graft dislocations). Secondary parameters/endpoints are surgical time, the recovery of visual acuity and endothelial graft quality at 3 and 6 months follow-up, and a detailed evaluation of the extent/duration of surgical tissue manipulations. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The use of iOCT during surgery does not entail additional risk to the patient. Participants to this study will adhere to the standard of care after corneal transplant surgery. In addition, they will receive study specific measurements and questionnaires. The additional measurements and questionnaires will be combined with regular follow up moments.

NCT ID: NCT03450954 Completed - Bullous Keratopathy Clinical Trials

Long Term Results of Amniotic Membrane Transplant in Bullous Keratopathy Patients

Start date: October 1, 2016
Phase: N/A
Study type: Observational

A retrospective study including 22 patients who have undergone amniotic membrane transplant in our unit up till 2016. Confocal microscopy and anterior segment optical coherence tomography (ASOCT) were performed to assess the retention of amniotic membrane and to detect any corneal structural changes. Comparison was made with 5 controls who had bullous keratopathy awaiting endothelial keratoplasty.

NCT ID: NCT03407755 Recruiting - Clinical trials for Fuchs' Endothelial Dystrophy

Air Versus SF6 for Descemet's Membrane Endothelial Keratoplasty (DMEK)

Start date: September 15, 2017
Phase: N/A
Study type: Interventional

This blinded, randomized study compares the use of air and sulfur hexaflouride (SF6) tamponade in Descemet Membrane Endothelial Keratoplasty.

NCT ID: NCT03248037 Completed - Clinical trials for Fuchs' Endothelial Dystrophy

Trial of Netarsudil for Prevention of Corticosteroid-induced Intraocular Pressure Elevation

Start date: September 5, 2017
Phase: Phase 3
Study type: Interventional

Cornea transplant recipients who are using topical corticosteroids long-term to prevent transplant rejection will be randomized to use netarsudil or placebo.